Aktis Oncology: The company raised $84 million of Series A venture funding from Novartis, MRL Ventures Fund and Merck & Co. on August 25, 2022. Timefolio Capital, Octagon Capital Investments, Vida Ventures, Cowen Healthcare Investments, TCG Crossover Management, MPM Capital, Mirae Asset Venture Investment, Pappas Capital, EcoR1 Capital, Octagon Capital Advisors, and ArrowMark Partners also participated in the round. The company is a developer of targeted radiopharmaceuticals designed to treat a broad range of solid tumor cancers.
Digital Diagnostics: The company raised $76.4 million of Series B venture funding in a deal led by Kohlberg Kravis Roberts on August 22, 2022. Optum Ventures, OSF Ventures, Edward-Elmhurst Health Venture Capital, Gundersen Health System, Kinderhook Industries, and 4 other investors also participated in the round. The company is an operator of an artificial intelligence-based diagnostic platform intended to transform the quality, accessibility, equity, and affordability of healthcare worldwide.
Happy Health: The company raised $60 million of Series A venture funding in a deal led by ARCH Venture Partners on August 24, 2022. Samsung Catalyst Fund, Lauder Partners and Risk & Return also participated in the round. The company is a developer of the Happy Ring wearable device that uses custom-designed biometric sensors and proprietary adaptive AI to capture brain signals from the peripheral nervous system and translate those into real-time objective measures of mood state.
eTheRNA: The company raised EUR 39.9 million of Series B2 venture funding in a deal led by Novalis LifeSciences on August 23, 2022, putting the company’s pre-money valuation at EUR 73.98 million. Grand Pharma, Omega Funds, Fund+, EQT Life Sciences, Kenneth Chien and PMV also participated in the round. The company is a developer of immunotherapies designed to provide targeted and safe mRNA therapies for the human immune system.
3T Biosciences: The company raised $40 million of Series A venture funding in a deal led by Westlake Village BioPartners and Lightspeed Venture Partners on August 25, 2022. The company is a developer and provider of drugs and medical research and development facilities intended to offer cures for cancer-related diseases.
AtomVie Global Radiopharma: The company raised $40 million of Series A venture funding from Avego Management on August 24, 2022. The company is a contract development and manufacturing organization for the GMP manufacturing and distribution of clinical and commercial radiopharmaceuticals from early clinical development to commercial scale.
Recuro Health: The company received $27.3 million of development capital from undisclosed investors on August 24, 2022. The company is a developer of a digital health platform designed for employers, providers and managed care organizations.
Plume: The company raised $24 million of Series B venture funding in a deal led by Transformation Capital on August 23, 2022, putting the company’s pre-money valuation at $41 million. General Catalyst and Town Hall Ventures also participated in the round. The company is a telehealth business that focuses on the transgender community and offers virtual primary care telehealth services.
SaNOtize: The company raised $24 million of Series B venture funding in a deal led by OurCrowd and Horizons Ventures on August 24, 2022. ABC International, La Jolla Holding Co., and other undisclosed investors also participated in the round. The company is a developer of a nitric oxide-releasing solution technology designed to treat upper respiratory and dermal infections.
Eyenuk: The company raised $22.4 million of venture funding from undisclosed investors on August 23, 2022. The company is a developer of an AI eye screening technology designed for autonomous disease detection, risk assessment and disease surveillance.
Miku: The company raised $20 million of Series B venture funding from TQ Ventures and other undisclosed investors on August 23, 2022. The company is a developer of a breathing and sleep tracking device designed to monitor a baby’s vitals and nursery conditions.
Orange Grove Bio: The company raised $16.6 million of venture funding from undisclosed investors on August 25, 2022. The company is an operator of a preclinical drug investment and development platform intended to drive down the cost of drug discovery and advance therapies into clinical trials.
GATC Health: The company closed on $10 million of an undisclosed targeted amount of venture funding on August 23, 2022. The company is an operator of a multiomic advanced technology platform designed to provide insight into individualized, specific health risks.
Innervace: The company raised $10 million of Series A venture funding from undisclosed investors on August 22, 2022, putting the company’s pre-money valuation at $12 million. The company is a developer of regenerative therapies designed to develop implantable tissue-engineered brain pathways for neurodegenerative disorders.
MedMinder: The company raised $10 million of venture funding from undisclosed investors on August 24, 2022. A $20 million term loan was provided by SWK Holdings. The company is a developer of a pill dispensing system designed to simplify medication management and improve medication adherence.
Advanced NanoTherapies: The company raised $9.8 million of Series A venture funding from undisclosed investors on August 22, 2022. The company is a developer of biodegradable functionalized nanoparticle technology designed for cardiovascular and endovascular applications.
Biotia: The company raised $8.0 million in Series A venture funding in a deal led by OCA Ventures on August 23, 2022, putting the company’s pre-money valuation at $15 million. The company is a developer of a laboratory technology designed to provide tailored sequencing to reduce hospital-acquired infections.
Cello Therapeutics: The company raised around $7 million of Series A-1 venture funding from undisclosed investors on August 22, 2022, putting the company’s pre-money valuation at $50 million. The company develops biomimetic cell membrane-coated nanoparticles for cancer drug delivery.
Levee Medical: The company raised $6.6 million of Series A venture funding from undisclosed investors on August 23, 2022. The company is a developer of urological devices designed to improve recovery outcomes post-prostatectomy.
